Answers are grounded in this paper and cite their sources.
Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov numbers, NCT00905372 and NCT00904683.).
No takes yet. Share an insight, caveat, or question.
Doody et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: